Esperion Therapeutics, Inc. (ESPR)
USD 1.0
(-2.05%)
USD 1.0
(-2.05%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -209.24 Million USD | 27.3% |
| 2022 | -287.81 Million USD | 9.73% |
| 2021 | -318.82 Million USD | -91.84% |
| 2020 | -166.18 Million USD | -52.44% |
| 2019 | -109.02 Million USD | 45.98% |
| 2018 | -201.81 Million USD | -20.85% |
| 2017 | -166.98 Million USD | -122.72% |
| 2016 | -74.97 Million USD | -50.61% |
| 2015 | -49.78 Million USD | -36.86% |
| 2014 | -36.37 Million USD | -39.43% |
| 2013 | -26.08 Million USD | -122.18% |
| 2012 | -11.74 Million USD | -8.55% |
| 2011 | -10.81 Million USD | 0.0% |
| 2002 | -28.72 Million USD | -15.22% |
| 2001 | -24.93 Million USD | 9.59% |
| 2000 | -27.57 Million USD | -158.44% |
| 1999 | -10.67 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -61.92 Million USD | -201.48% |
| 2024 Q1 | 61.02 Million USD | 208.3% |
| 2023 FY | -209.24 Million USD | 27.3% |
| 2023 Q1 | -89.22 Million USD | -30.32% |
| 2023 Q4 | -56.34 Million USD | -36.59% |
| 2023 Q2 | -49.93 Million USD | 44.03% |
| 2023 Q3 | -41.25 Million USD | 17.39% |
| 2022 FY | -287.81 Million USD | 9.73% |
| 2022 Q4 | -68.46 Million USD | 0.22% |
| 2022 Q3 | -68.61 Million USD | 14.53% |
| 2022 Q2 | -80.27 Million USD | -13.9% |
| 2022 Q1 | -70.47 Million USD | -8.22% |
| 2021 Q4 | -65.11 Million USD | 6.15% |
| 2021 Q3 | -69.38 Million USD | -58.89% |
| 2021 Q2 | -43.66 Million USD | 51.98% |
| 2021 Q1 | -90.93 Million USD | 12.96% |
| 2021 FY | -318.82 Million USD | -91.84% |
| 2020 Q1 | -78.24 Million USD | -26.32% |
| 2020 FY | -166.18 Million USD | -52.44% |
| 2020 Q3 | -85.43 Million USD | -168.56% |
| 2020 Q4 | -104.47 Million USD | -22.28% |
| 2020 Q2 | 124.61 Million USD | 259.25% |
| 2019 Q4 | -61.94 Million USD | 9.41% |
| 2019 Q1 | 87.37 Million USD | 245.54% |
| 2019 Q2 | -54.22 Million USD | -162.05% |
| 2019 Q3 | -68.37 Million USD | -26.11% |
| 2019 FY | -109.02 Million USD | 45.98% |
| 2018 Q2 | -45.73 Million USD | 0.87% |
| 2018 FY | -201.81 Million USD | -20.85% |
| 2018 Q1 | -46.13 Million USD | -21.74% |
| 2018 Q4 | -60.03 Million USD | -20.29% |
| 2018 Q3 | -49.91 Million USD | -9.14% |
| 2017 Q1 | -40.54 Million USD | -40.01% |
| 2017 FY | -166.98 Million USD | -122.72% |
| 2017 Q4 | -37.89 Million USD | 16.21% |
| 2017 Q3 | -45.21 Million USD | -4.34% |
| 2017 Q2 | -43.33 Million USD | -6.9% |
| 2016 Q2 | -14.03 Million USD | 3.77% |
| 2016 FY | -74.97 Million USD | -50.61% |
| 2016 Q4 | -28.95 Million USD | -66.39% |
| 2016 Q3 | -17.4 Million USD | -23.99% |
| 2016 Q1 | -14.58 Million USD | -11.15% |
| 2015 Q3 | -12.8 Million USD | -3.28% |
| 2015 FY | -49.78 Million USD | -36.86% |
| 2015 Q2 | -12.39 Million USD | -8.1% |
| 2015 Q4 | -13.12 Million USD | -2.51% |
| 2015 Q1 | -11.46 Million USD | -21.24% |
| 2014 Q4 | -9.45 Million USD | 3.56% |
| 2014 Q1 | -7.87 Million USD | 18.74% |
| 2014 Q3 | -9.8 Million USD | -6.15% |
| 2014 FY | -36.37 Million USD | -39.43% |
| 2014 Q2 | -9.23 Million USD | -17.32% |
| 2013 FY | -26.08 Million USD | -122.18% |
| 2013 Q1 | -4.23 Million USD | -52.74% |
| 2013 Q2 | -6.92 Million USD | -63.26% |
| 2013 Q3 | -5.23 Million USD | 24.31% |
| 2013 Q4 | -9.68 Million USD | -84.97% |
| 2012 Q2 | -3.16 Million USD | -29.29% |
| 2012 Q4 | -2.77 Million USD | 17.19% |
| 2012 Q3 | -3.35 Million USD | -5.85% |
| 2012 Q1 | -2.44 Million USD | 0.0% |
| 2012 FY | -11.74 Million USD | -8.55% |
| 2011 FY | -10.81 Million USD | 0.0% |
| 2003 Q3 | -6.56 Million USD | 22.19% |
| 2003 Q2 | -8.43 Million USD | -13.89% |
| 2003 Q1 | -7.4 Million USD | -11.89% |
| 2002 Q2 | -7.82 Million USD | -7.13% |
| 2002 FY | -28.72 Million USD | -15.22% |
| 2002 Q3 | -6.98 Million USD | 10.79% |
| 2002 Q4 | -6.61 Million USD | 5.17% |
| 2002 Q1 | -7.3 Million USD | -15.12% |
| 2001 Q2 | -6.32 Million USD | -5.75% |
| 2001 FY | -24.93 Million USD | 9.59% |
| 2001 Q4 | -6.34 Million USD | -1.0% |
| 2001 Q3 | -6.28 Million USD | 0.7% |
| 2001 Q1 | -5.98 Million USD | -7.48% |
| 2000 Q2 | -6.51 Million USD | -38.8% |
| 2000 Q1 | -4.69 Million USD | 0.0% |
| 2000 Q3 | -10.8 Million USD | -65.86% |
| 2000 Q4 | -5.56 Million USD | 48.49% |
| 2000 FY | -27.57 Million USD | -158.44% |
| 1999 FY | -10.67 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 534.53% |
| Embecta Corp. | 70.4 Million USD | 397.227% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 1214.266% |
| Dynavax Technologies Corporation | -6.38 Million USD | -3175.129% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 598.744% |
| PainReform Ltd. | -9.34 Million USD | -2139.384% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -2558.806% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -4543.719% |
| SCYNEXIS, Inc. | 67.04 Million USD | 412.119% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -6653.133% |
| Cosmos Health Inc. | -18.54 Million USD | -1028.468% |
| Journey Medical Corporation | -3.85 Million USD | -5330.781% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -4543.719% |
| Safety Shot Inc | -15.08 Million USD | -1287.306% |
| Alpha Teknova, Inc. | -36.78 Million USD | -468.918% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | -49.812% |
| Bright Green Corporation | -13.12 Million USD | -1493.949% |
| Procaps Group, S.A. | 42.54 Million USD | 591.885% |
| Theratechnologies Inc. | -23.95 Million USD | -773.432% |
| Harrow Health, Inc. | -24.41 Million USD | -757.187% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -4227.777% |
| Biofrontera Inc. | -20.13 Million USD | -939.432% |
| DURECT Corporation | -27.62 Million USD | -657.486% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 16000.304% |
| Cronos Group Inc. | -73.96 Million USD | -182.909% |
| OptiNose, Inc. | -35.48 Million USD | -489.713% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 79.122% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -395.86% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 974.929% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 4331.507% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 132507.788% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -3232.335% |
| Radius Health, Inc. | -25.79 Million USD | -711.322% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -3295.196% |
| ProPhase Labs, Inc. | -16.78 Million USD | -1146.86% |
| Phibro Animal Health Corporation | 2.41 Million USD | 8760.927% |
| Procaps Group S.A. | 42.54 Million USD | 591.885% |
| Alvotech | -551.73 Million USD | 62.074% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -1935.882% |
| Viatris Inc. | 54.7 Million USD | 482.537% |
| Rockwell Medical, Inc. | -8.43 Million USD | -2379.535% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -1220.677% |
| SIGA Technologies, Inc. | 68.06 Million USD | 407.407% |
| Tilray Brands, Inc. | -244.98 Million USD | 14.586% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 1841.846% |
| Shineco, Inc. | -22.44 Million USD | -832.103% |
| PetIQ, Inc. | 2.13 Million USD | 9919.24% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -4764.155% |
| Incannex Healthcare Limited | -18.45 Million USD | -1033.583% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 183.8% |
| Alimera Sciences, Inc. | -20.13 Million USD | -939.38% |
| Silver Spike Investment Corp. | 7.34 Million USD | 2950.748% |
| Assertio Holdings, Inc. | -331.94 Million USD | 36.962% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -3073.924% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -2463.312% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | -1069.049% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -943.251% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | -30.555% |
| Hempacco Co., Inc. | -13.12 Million USD | -1494.139% |
| Talphera, Inc. | -18.39 Million USD | -1037.403% |
| Alvotech | -551.73 Million USD | 62.074% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 687.083% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 164.057% |
| Currenc Group, Inc. | -15.3 Million USD | -1267.049% |
| Kamada Ltd. | 8.28 Million USD | 2625.93% |
| Indivior PLC | 2 Million USD | 10562.4% |
| Evoke Pharma, Inc. | -7.79 Million USD | -2585.319% |
| Flora Growth Corp. | -57.03 Million USD | -266.87% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -943.251% |
| Evolus, Inc. | -61.68 Million USD | -239.22% |
| HUTCHMED (China) Limited | 100.78 Million USD | 307.628% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 252.131% |
| Akanda Corp. | -32.27 Million USD | -548.327% |